Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FGFR-TKI resistance in cancer: current status and perspectives.

Journal of hematology & oncology - 10 Feb 2021

Yue Sitong, Li Yukun, Chen Xiaojuan, Wang Juan, Li Meixiang, Chen Yongheng, Wu Daichao

Abstract excerpt

Fibroblast growth factor receptors (FGFRs) play key roles in promoting the proliferation, differentiation, and migration of cancer cell. Inactivation of FGFRs by tyrosine kinase inhibitors (TKI) has achieved great success in tumor-targeted therapy. However, resistance to FGFR-TKI has become a concern. Here, we review the mechanisms of FGFR-TKI resistance in cancer, including gatekeeper mutations, alternative...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Neoplasms

Share to Protein Kinase Inhibitors

Share to Protein-Tyrosine Kinases

Share to Receptors, Fibroblast Growth Factor

Share to Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 33568192
DOI: 10.1186/s13045-021-01040-2
PMCID: PMC7876795

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FGFR-TKI resistance in cancer: current status and perspectives.PMID 33568192Read ↗

Future applications of FGF/FGFR inhibitors in cancer.Semantic proximity Read ↗

FGFR-driven lung cancer: Dissecting resistance and exploring therapeutic avenues.Semantic proximity Read ↗

FGFR a promising druggable target in cancer: Molecular biology and new drugs.Semantic proximity Read ↗

Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions.Semantic proximity Read ↗

Molecular Targeting of the Fibroblast Growth Factor Receptor (FGFR) Pathway Across Various CancersSemantic proximity Read ↗

FGFR families: biological functions and therapeutic interventions in tumorsSemantic proximity Read ↗

RAS-MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade.Semantic proximity Read ↗

FGFR blockade inhibits targeted therapy-tolerant persister cells in basal FGFR1 and FGF2 high expressing cancers with driver oncogenesSemantic proximity Read ↗

RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations.Semantic proximity Read ↗

Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers.Semantic proximity Read ↗

Targeting Cellular Trafficking of Fibroblast Growth Factor Receptors as a Strategy for Selective Cancer TreatmentSemantic proximity Read ↗

Design, synthesis and antitumor activity of a novel FGFR2-selective degrader to overcome resistance of the FGFR2V564F gatekeeper mutation based on a pan-FGFR inhibitor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.